Macula Retina Vitreous Research Institute — Torrance, California

Macula Retina Vitreous Research Institute is a clinical research site located in Torrance, California, United States 90503-3270.

Crixeo Clinical Trials Trust Score: 15/100 (FAILING). This profile has not yet been claimed by the site owner.

Macula Retina Vitreous Research Institute has participated in 5 clinical trials with 4 currently active.

Therapeutic areas: Diabetic Macular Edema, Geographic Atrophy, Neovascular Age-related Macular Degeneration.

Sponsors: Genentech, Inc., Annexon, Inc., Regeneron Pharmaceuticals.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Torrance

Browse all research sites in California · View every site in Torrance

Sponsor Feasibility Report

Trust Score: 15/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Macula Retina Vitreous Research Institute?

Macula Retina Vitreous Research Institute has a Crixeo Trust Score of 15/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Macula Retina Vitreous Research Institute conducted?

Macula Retina Vitreous Research Institute has 5 clinical trials on record, with 4 currently active. Their work covers Diabetic Macular Edema, Geographic Atrophy, Neovascular Age-related Macular Degeneration.

Is Macula Retina Vitreous Research Institute accredited by Crixeo Clinical Trials?

Macula Retina Vitreous Research Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Macula Retina Vitreous Research Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.